Clinical News

Identifying the Problem Is Key to Quality Improvement in Cancer Care

Meg Barbor, MPH

January 2019, Vol 9, No 1 - Quality Care

“There are a number of ways to go wrong when you’re trying to improve something,” said Kaveh G. Shojania, MD, Director, Centre for Quality Improvement and Patient Safety, University of Toronto, Canada, and Editor-in-Chief, BMJ Quality & Safety, who delivered the keynote address at the 2018 ASCO Quality Care Symposium. When it comes to improving quality in cancer care, there are no magic bullets. Many approaches have little to no impact. But recognizing and avoiding the most common pitfalls in quality improvement efforts can improve the chances for success, according to Dr Shojania. [ Read More ]

Venclexta Approved in Combination for Older Adults with Acute Myeloid Leukemia

December 2018, Vol 8, No 12 - FDA Approvals, News & Updates, Leukemia

On November 21, 2018, the FDA accelerated the approval of venetoclax (Venclexta; AbbVie/Genentech), in combination with azacitidine (Vidaza), decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients aged ≥75 years or those with comorbidities that preclude intensive induction chemotherapy. [ Read More ]

Adcetris First FDA-Approved Drug for CD30-Expressing Peripheral T-Cell Lymphomas

December 2018, Vol 8, No 12 - FDA Approvals, News & Updates

On November 16, 2018, the FDA approved brentuximab vedotin (Adcetris; Seattle Genetics), in combination with chemotherapy, for patients with untreated systemic ­anaplastic large-cell lymphoma (sALCL) or with other CD30-­expressing peripheral T-cell lymphomas (PTCLs), including angioim­munoblastic T-cell lymphoma and PTCL not otherwise specified. This is the first FDA-approved drug for newly diagnosed PTCL, including sALCL. Brentuximab vedotin was previously approved by the FDA for classical Hodgkin lymphoma. [ Read More ]

Xospata First Therapy Approved for Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

December 2018, Vol 8, No 12 - FDA Approvals, News & Updates

On November 28, 2018, the FDA approved gilteritinib (Xospata; Astellas Pharma) for adult patients with relapsed or refractory acute myeloid leukemia (AML) and an FLT3 mutation, as identified by an FDA-approved test. The FDA approved gilteritinib using its fast track and priority review and granted it an orphan drug designation. [ Read More ]

Daurismo New Treatment Approved for Older Adults with Acute Myeloid Leukemia

December 2018, Vol 8, No 12 - FDA Approvals, News & Updates, Leukemia

On November 21, 2018, the FDA approved glasdegib (Daurismo; Pfizer), an oral Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC), for patients with newly diagnosed acute myeloid leukemia (AML) who are aged ≥75 years or who have comorbidities that preclude use of intensive induction chemotherapy. The FDA approved glasdegib using its priority review and granted it an orphan drug designation. [ Read More ]

Talzenna Approved for HER2-Negative, Locally Advanced Breast Cancer with Germline BRCA Mutations

December 2018, Vol 8, No 12 - Breast Cancer, FDA Approvals, News & Updates

On October 16, 2018, the FDA approved talazoparib (Talzenna; Pfizer), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with HER2-­negative, locally advanced or metastatic breast cancer and deleterious or suspected deleterious germline BRCA mutation, as identified by an FDA-approved test. [ Read More ]